Tg Therapeutics (TGTX) Operating Leases (2019 - 2026)

Tg Therapeutics' Operating Leases history runs 8 years deep, the most recent figure standing at $6.6 million for Q1 2026.

• On a quarterly basis, Operating Leases fell 16.09% year-over-year to $6.6 million in Q1 2026; TTM through Mar 2026 was $6.6 million, a 16.09% decrease from a year earlier, with the FY2025 full-year figure at $7.0 million, down 13.67% from the prior year.
• Operating Leases declined to $6.6 million in Q1 2026 per TGTX's latest filing, from $7.0 million in the prior quarter.
• Across five years, Operating Leases topped out at $10.6 million in Q3 2022 and bottomed at $6.6 million in Q1 2026.
• The 5-year median for Operating Leases is $9.0 million (2024), against an average of $8.8 million.
• Across the five-year window, Operating Leases grew 5.61% in 2022 and fell 16.09% in 2026, its largest moves.
• Year by year, Operating Leases stood at $10.3 million in 2022, then dropped by 10.76% to $9.2 million in 2023, then dropped by 11.89% to $8.1 million in 2024, then retreated by 13.67% to $7.0 million in 2025, then retreated by 6.07% to $6.6 million in 2026.
• Per Business Quant, the three latest TGTX Operating Leases figures stand at $6.6 million (Q1 2026), $7.0 million (Q4 2025), and $7.3 million (Q3 2025).